Jipan Xie
Vice President

Los Angeles
Education
Ph.D., health policy and administration, the University of North Carolina at Chapel Hill; M.D., Peking Union Medical College
Summary of Experience
Dr. Xie is a health economist with extensive experience in health economics and outcomes research. Her expertise includes economic evaluations, health technology assessments in both the US and global markets, and comparative outcomes research using clinical trial and real-world data. She has worked in a variety of disease areas, such as mental health, oncology, cardiovascular and other chronic diseases, as well as infectious diseases. Her work has been widely published in leading clinical, economic, and managed care journals, including Circulation, Stroke, PharmacoEconomics, Value in Health, and American Journal of Managed Care. Dr. Xie has extensive experience in emerging markets, particularly in China. Her work in this area includes outcomes research using high-quality EMR data, economic evaluations, market access of oncology drugs, burden of illness based on claims and surveys, and the China National Stroke Registry design and revision of the treatment guidelines for hypertension and diabetes. She was a coeditor of PharmacoEconomics journal's special issue on health care in China. She also serves as an adjunct professor at Shanghai Jiao Tong University School of Public Health. Prior to joining Analysis Group, Dr. Xie was a health service researcher at the Centers for Disease Control and Prevention, leading the health services and outcomes research in the Division for Heart Disease and Stroke Prevention.
Selected Publishing
-
The Development of Health Technology Assessment in Asia: Current Status and Future Trends
Value in Health Regional Issues, Volume 21, May 2020
2020 -
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies
Haemophilia, 27 November 2020
2020Song X, Zhong J, Xue F, Chen L, Li H, Yuan D, Xie J, Shi J, Zhang L, Wu E, Yang R
-
Real‐world analysis of haemophilia patients in China: A single centre’s experience
Haemophilia, 20 May 2020
2020Song X, Liu W, Xue F, Zhong J, Yang Y, Liu Y, Xie, J, Wu E, Zhang L, Shi J, Yang R
-
Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
Rheumatology and Therapy, January 5, 2019
2019Sunkureddi P, Latrémouille-Viau D, Meiselbach MK, Xie J, Hur P, Joshi R
-
Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review
Drugs - Real World Outcomes, January 7, 2019
2019Joshi R, Latrémouille-Viau D, Meiselbach MK, Xie J, Park Y, Sunkureddi P
-
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
PharmacoEconomics. 2019 Feb;37(2):239-253
2019Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, Guérin A, Li N, Joseph G
-
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
PharmacoEconomics, 2019
2019 -
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Advances in Therapy, 2019
2019Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S
-
Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure
Journal of Parenteral and Enteral Nutrition, 2019
2019Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB
-
Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
Blood Advances, 2019
2019Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Xie J
-
Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States
Current Medical Research and Opinion. Apr 2018;34(4):585-592
2018 -
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States
Journal of Medical Economics. Jun 2018;21(6):577-586
2018Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K
-
Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysis
Clinical Therapeutics. Apr 2018;40(4):628-639 e623
2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA
-
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome
Therapeutics and Clinical Risk Management. 2018 Jul 25;14:1267-1277
2018Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE
-
A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment
The Journal of Clinical Hypertension. 2018 Jun;20(6):1058-1066
2018Ayyagari R, Xie J, Cheng D, Wu EQ, Huang XY, Chen S
-
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis
Current Medical Research and Opinion. 2018 Sep;34(9):1645-1652
2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA
-
Policy Considerations: Ex-US Payers and Regulators
Decision Making in a World of Comparative Effectiveness Research
2017Xie J, Chalkidou K, Kamae I, Dittrich R, Mahbub R, Vasan A, Metallo C
-
Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer
Expert Opinion on Pharmacotherapy. Aug 2017;18(12):1167-1178
2017Li N, Du EX, Chu L, Peeples M, Xie J, Barghout V, Tang DH
-
Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014
Journal of the American Academy of Dermatology. Jul 2017;77(1):55-62 e53
2017Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB
-
Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.
Advances in Therapy. Dec 2017;34(12):2566-2584
2017Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA
-
Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors
American Health and Drug Benefits. November 2017;10(8):408-415
2017Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB
-
Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
European Child and Adolescent Psychiatry. Aug 2017;26(8):875-897
2017Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V
-
First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study
Current Medical Research and Opinion. Dec 2017;33(12):2137-2143
2017Tang DH, Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V
-
Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites
Clinical Therapeutics, 2016 04; 38(4): 905-917. e-pub ahead of print 2016/03/08
2016 -
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Journal of Blood Medicine, 2016 07; 7: 129-137. e-pub ahead of print 2016/07/23
2016Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J
-
Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey
Clinical Therapeutics, 2016 02; 5(2): 209-220
2016Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ.
-
Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada
Journal of Medical Economics, 2016 05: 1-17. doi: 10.1080/13696998.2016.1187151
2016Hurry M, Zhou ZY, Zhang J, Zhang C, Liangyi F, Rebeira M, Xie J
-
Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension
Curr Med Res Opin. 2014 Apr;30(4):637-43
2014Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ
-
A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy
Eur J Gastroenterol Hepatol. 2013 Jun; 25(6):739-47
2013Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J.
-
-
Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases
UroToday.com, Beyond the Abstract, July 2012
2012 -
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of ADHD
Pharmacoeconomics. 2012 Aug 1;30(8):e1-15
2012Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ
-
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity
J Med Econ. 2012; 15(6):1078-87
2012Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.
-
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative advanced breast cancer
Journal of Medical Economics, 1-26, November 16, 2012
2012 -
Re: Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs. zoledronic acid for prevention of skeletal-related events
Journal of Medical Economics; December 5, 2012 [Letter to the Editor]
2012 -
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate-severe psoriasis
JAAD. 2011 May 24
2011Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM
-
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases
Journal of Managed Care Pharmacy. 2011;17(8):621-34
2011Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW
-
Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement
Curr Med Res Opin. 2010 Sep;26(9):2203-12
2010Chang J, Yang W, Fellers T, Kahler K, Orloff J, Xie J, Tsaneva M, Yu A, Wu EQ
-
Systematic review: the costs of ulcerative colitis in Western countries
Aliment Pharmacol Ther. 2010 Apr;31(7):693-707
2010 -
Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram
J Med Econ. 2010 Sep 29. [Epub ahead of print]
2010Yu A, Xie J, Bensimon A, Parikh K, Wu E, Ben-Hamadi R, Blum S, Haim Erder
-
Economic burden of psoriasis compared to the general population and stratified by disease severity
Curr Med Res Opin. 2009 Oct;25(10):2429-38
2009 -
Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States
Stroke, 2006 Oct;37(10):2567-72
2006Xie J, Wu E, Zheng Z, Croft J, Greenlund K, Mensah G, Labarthe D
News
-
February 09, 2021
-
January 02, 2020
-
November 14, 2019
-
December 11, 2018